Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.aareydrugs.com | |
Market Cap | 86.05 Cr. | |
Enterprise Value(EV) | 109.89 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 1.62 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | 20.93 | Trailing Twelve Months Ending 2022-09 |
Industry PE | 32.78 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 45.92 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 0.74 | Calculated using Price: 33.90 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 2.54 Cr. | 25,384,684 Shares |
FaceValue | 10 | |
Company Profile | ||
Aarey Drugs & Pharmaceuticals Ltd. was established in 1990. The company is engaged in the manufacturing of drugs and intermediates such as metronidazole, metronidazole benzoate, methyl, and nitro imidazole. The company is based in Thane, India. |
1 Day |
|
-3.71% |
1 Week |
|
-9.40% |
1 Month |
|
-13.02% |
3 Month |
|
-11.18% |
6 Month |
|
-6.25% |
1 Year |
|
-34.02% |
2 Year |
|
+25.70% |
5 Year |
|
-41.10% |
10 Year |
|
-29.83% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 3.10 | 3.12 | 3.58 | 12.90 | 9.80 | 8.07 | 6.65 | 6.98 | 6.30 | |
Return on Capital Employed (%) | 5.83 | 6.69 | 7.23 | 22.21 | 14.14 | 12.05 | 8.48 | 9.46 | 9.86 | |
Return on Assets (%) | 0.98 | 0.98 | 1.07 | 4.09 | 3.96 | 4.15 | 3.41 | 3.05 | 2.74 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 35 | 35 | 37 | 49 | 80 | 87 | 92 | 99 | 114 | 117 | |
Non Curr. Liab. | 0 | 0 | 2 | 1 | 2 | 1 | 3 | 1 | 5 | ||
Curr. Liab. | 72 | 80 | 88 | 92 | 88 | 58 | 100 | 131 | 130 | 107 | |
Minority Int. | |||||||||||
Equity & Liab. | 107 | 115 | 125 | 143 | 170 | 146 | 194 | 233 | 245 | 228 | |
Non Curr. Assets | 5 | 6 | 8 | 13 | 13 | 13 | 13 | 15 | 19 | 19 | |
Curr. Assets | 102 | 109 | 117 | 130 | 157 | 133 | 181 | 218 | 226 | 210 | |
Misc. Exp. not W/O | 0 | 0 | |||||||||
Total Assets | 107 | 115 | 125 | 143 | 170 | 146 | 194 | 233 | 245 | 228 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 200 | 213 | 246 | 396 | 349 | 355 | 300 | 348 | 493 | 454 | |
Other Income | 2 | 3 | 3 | 3 | 3 | 4 | 7 | 7 | 3 | 3 | |
Total Income | 201 | 216 | 249 | 399 | 352 | 359 | 307 | 355 | 495 | 457 | |
Total Expenditure | -198 | -212 | -245 | -386 | -341 | -347 | -297 | -344 | -481 | -446 | |
PBIDT | 3 | 4 | 4 | 13 | 11 | 12 | 10 | 12 | 14 | 11 | |
Interest | -1 | -1 | -2 | -4 | -2 | -2 | -2 | -2 | -2 | -2 | |
Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -2 | -2 | |
Taxation | 0 | 0 | -1 | -3 | -2 | -2 | -1 | -2 | -3 | -3 | |
Exceptional Items | |||||||||||
PAT | 1 | 1 | 1 | 5 | 6 | 7 | 6 | 7 | 7 | 4 | |
Adjusted EPS | 1 | 1 | 1 | 3 | 3 | 3 | 2 | 3 | 3 | 2 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 3 | 0 | 3 | 6 | 1 | -20 | 1 | 3 | 5 | -4 | |
Cash Fr. Inv. | -3 | 2 | -2 | -3 | -5 | -1 | -1 | -1 | -3 | -2 | |
Cash Fr. Finan. | -1 | -1 | -2 | -2 | 4 | 23 | -2 | -2 | -2 | 6 | |
Net Change | -1 | 0 | -1 | 1 | -1 | 2 | -3 | 0 | 0 | 0 | |
Cash & Cash Eqvt | 1 | 1 | 0 | 2 | 1 | 3 | 0 | 1 | 1 | 0 |
Fri, 13 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Regulation 74(5) of SEBI (DP) Regulations 2018. |
Fri, 30 Dec 2022
Closure of Trading Window Closure of Trading window |
Thu, 17 Nov 2022
Regulation 23(9) Of SEBI (LODR) Regulation 2015. Regulation 23(9) of SEBI (LODR) Regulation 2015. |
Mon, 30 Jan 2023 |
|
|
|
|
|